Apulmiq License Agreement - Additional Information (Details) - Apulmiq License Agreement [Member] - Grifols Patents [Member] - USD ($) shares in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement description	(1) a Licensed Product for the treatment of either NCFB or pulmonary infections associated with NCFB (the “Initial Indication”) and (2) any Licensed Product for another indication, of which none are currently approved (an “Additional Indication”), including the conduct of a confirmatory Phase 3 clinical trial in the Initial Indication.
Upfront cash payment	$ 3,300,000
Upfront payment common stock shares issued	1
Upfront payment value of common stock issued	$ 2,100,000
Developmental milestone payments	50,000,000
Sales milestone payments	$ 100,000,000
Tiered royalties payment term	10 years
Research and development expense	$ 5,400,000
License agreement, contingent consideration liability	0
Accrued legal fees	500,000
Legal fees	200,000	$ 300,000
First Achievement of Annual Global Net Sales of $100.0 Million [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Global net sales target amount	100,000,000
First Achievement of Annual Global Net Sales of $300.0 Million [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Global net sales target amount	300,000,000
First Achievement of Annual Global Net Sales of $500.0 Million [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Global net sales target amount	$ 500,000,000